# Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

> **NCT04410445** · PHASE3 · TERMINATED · sponsor: **Nektar Therapeutics** · enrollment: 765 (actual)

## Conditions studied

- Melanoma
- Melanoma Stage III
- Melanoma Stage IV
- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** Bempegaldesleukin
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT04410445
- **Lead sponsor:** Nektar Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-27
- **Primary completion:** 2022-09-22
- **Final completion:** 2022-09-22
- **Target enrollment:** 765 (ACTUAL)
- **Why stopped:** (Sponsor decision)
- **Last updated:** 2023-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04410445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04410445, "Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04410445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*